Transcenta Holding-B (02617): Jienertai has issued its first clinical prescriptions in multiple provinces, with simultaneous stocking completed at DTP pharmacies in many locations across the country.

Zhitong Finance APP News, LaNova Medicines-B (02617) announced that the Company's independently developed Class 1 new drug Jie'antai (Tinengotinib tablets) has received conditional marketing approval from the National Medical Products Administration (NMPA) for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma who have previously received systemic therapy and FGFR inhibitor therapy and who harbor fibroblast growth factor receptor (FGFR) 2 fusion or rearrangement. In September 2026, the "Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Biliary Tract Malignancies" was officially released, and Jie'antai was included in the guidelines as a Class II recommendation, Category 2A, for the treatment of advanced biliary tract malignancies. Jie'antai is the first therapeutic drug approved for marketing in China for this indication, and is expected to benefit patients with FGFR-mutant cholangiocarcinoma after resistance, filling the guideline gap in the treatment of advanced biliary tract malignancies.